experimental Group - Mila-Learn
DeviceEight tasks are used in Mila-Learn.
NCT Number: NCT05154721
Mila-Learn-01 is a double-blind clinical study (meaning that neither the patient nor the doctor or his/her team will know which game the child has), which enables us to see the effect of a serious game on the child's reading skills.
The patients who will participate in this research will receive, at random, one of the two serious study games, the experimental game (Mila-Learn) or the placebo game (Mila-Placebo). The tasks designed in the placebo game mirror those of Mila-Learn.
Each game comprises eight tasks to be completed on a touchscreen tablet. Each session lasts 25 minutes (±20%); five training sessions lasting 25 minutes are planned per week for eight weeks.
Looking for future studies?
Notify Me7 year–11 year
All sexes
Interventional
Not applicable
Centre médical pluridisciplinaire CogCharonne, Paris, France
The study consists of a randomised, double-blind clinical trial with a control group to evaluate the impact of the Mila-Learn game on children's skills. In order to maintain the blinding of the patient and his/her family, the study will be presented to them as evaluating the effect of serious games on a child's learning without explaining that the study is specifically interested in the Mila-Learn game, music and rhythm.
Each child included in the study will be randomised:
A randomisation list will be edited by the statistician. It will allow us to know whether the patient will be in the experimental arm or the control arm when sending out the tablets, depending on the chronological order of the inclusions, so that we can send the corresponding tablet to the patient.
In each group, the children will follow the same training protocol consisting of five training sessions per week on the game corresponding to their group. Each game comprises 8 tasks to be completed on a touchscreen tablet. Each session lasts 25 minutes (±20%).
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Eight tasks are used in Mila-Learn.
Eight tasks similar to Mila-Learn are used in the placebo group
Time frame: 8 weeks after the start of training (T2)
Absolute change in the number of pseudo-words correctly read by the children in the pseudo-word reading test, EVALEO 6-15, by Launay, Maeder, Roustit and Touzin, 2018.
Time frame: During the training phase, up to 8 weeks
Descriptive evaluation of any adverse events reported by the users.
Time frame: 8 weeks after the start of training (T2)
This endpoint relates to the child's phonological skills at T2 compared to T1, evaluated using the BALE [Battery of Analytical Tests on Written Language] initial or final phoneme deletion test.
Time frame: 8 weeks after the start of training (T2)
This endpoint relates to reading skills in terms of speed and accuracy. The analysis will focus on the percentage of words correctly read in two minutes (EVAL2M, Evaleo 6-15).
Time frame: 8 weeks after the start of training (T2)
This endpoint relates to phoneme-grapheme correspondence skills, evaluated using two pseudo-word transcription tests.
Time frame: 8 weeks after the start of training (T2)
This endpoint relates to the evolution of the child's self-esteem measured by the Rosenberg Self-Esteem scale.
Time frame: 16 weeks after the start of training (T3)
The primary endpoint is the absolute change in the number of pseudo-words correctly read by the children in the pseudo-word reading test, EVALEO 6-15, by Launay, Maeder, Roustit and Touzin, 2018.
Poppins
Industry
Effect of Music and Rhythm Training Delivered Through a Serious Game on the Reading Skills of Children With a Specific Learning Disorder Impacting Reading, a Multicentric Double-blind and Placebo-controlled Study (Mila-Learn-01)
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06592911
Communication Disorders, Dyslexia
Paris, France
View Trial DetailsNCT06902610
Communication Disorders, Dyslexia
Paris, France
View Trial DetailsNCT06596980
Communication Disorders, Dyslexia
Paris, France
View Trial DetailsNCT07546292
Communication Disorders, Dyslexia
Zurich, Switzerland
View Trial Details